FDA-cleared sleep diagnostics for the modern lab,  book a demo →

DormoVision X™: Gold Standard SpO₂ Accuracy Across All Skin Tones and Sleep Positions

A review of the clinical evidence supporting DormoVision X™ Home PSG and In-Lab PSG devices, with a focus on oxygen saturation accuracy, forehead sensor technology, and performance across different skin tones and sleeping positions.

Summary

This article reviews the validation studies supporting the photoplethysmography technology incorporated in DormoVision X™ Home PSG and DormoVision X™ In-Lab PSG devices. The validation procedures assessed oxygen-saturation performance against established reference methods across normal and reduced oxygen levels, different skin tones, and body positions.

The results demonstrated agreement with the gold standard arterial reference, with no systematic pigmentation related performance differences reported. Positional testing provided further evidence of measurement agreement across the evaluated postures. Together with the existing scientific literature, these findings provide a clinical foundation for confidence in oxygen-saturation monitoring with

DormoVision X™ Home PSG and DormoVision X™ In-Lab PSG across physiological conditions.

Clinical Validation Framework for DormoVision X™ SpO₂ Measurement

The DormoVision X™ Platform incorporates photoplethysmography (PPG) technology for recording oxygen saturation and pulse rate alongside comprehensive physiological sleep signals. Its pulse oximetry technology is supported by a dedicated clinical validation program combining arterial reference accuracy testing with additional assessment across body positions. These complementary studies evaluated performance across normal and reduced oxygen levels, different skin tones, and positions relevant to sleep assessment [1–3].

The studies were conducted by a specialist clinical testing laboratory with expertise in pulse oximeter validation (Vital Signs Research Group, San Francisco https://vitalsignsresearchgroup.com ), using prospective protocols with ethics committee approval and informed consent. The reports describe testing conducted in accordance with ISO 14155 and ISO 80601-2-61, providing a structured framework for clinical investigation and pulse oximeter performance assessment [2, 3].

The dedicated oxygen saturation studies collected 633 paired measurements from 22 subjects, evaluating performance across oxygen saturation levels spanning 70-100%, different skin tones, and body positions.

Assessment included root-mean-square error (RMSE), mean bias, and limits of agreement against the respective reference methods [2, 3]. Beyond this dedicated oximetry testing, the platform’s broader clinical validation program included studies enrolling 73 additional participants (47 adults and 26 children) to evaluate comprehensive physiological sleep measurements against reference polysomnography [4, 5].

97.6% AHI severity classification agreement vs. Nox A1 PSG  ·  Cohen’s κ ≈ 0.97 [4]

Additional support for the platform’s clinical performance comes from published validation of its earlier recording system against Nox A1 polysomnography. In the study, AHI severity classification agreed in 97.6% of fully analyzed recordings, with Cohen’s κ of approximately 0.97, supporting the platform’s broader capability for comprehensive sleep assessment [4].

Validation areas covered in this document
01
Forehead measurement site
Published clinical evidence comparing forehead and finger oximetry
02
Skin pigmentation
SpO2 accuracy against arterial blood across Fitzpatrick skin types I–VI
03
Body position
SpO2 agreement with a reference finger oximeter across five positions
01
Validation area Forehead measurement site
Clinical Evidence for the Forehead Oxygen Saturation Sensor

Pulse oximetry estimates arterial oxygen saturation from the differential absorption of red and infrared light by oxygenated and deoxygenated hemoglobin. The pulsatile component helps distinguish arterial blood-volume changes from the surrounding tissue signal. This principle can be implemented using transmission geometry, commonly at the finger, or reflectance geometry, as used at the forehead [6].

Forehead reflectance oximetry is an established clinical approach. Its validity depends on the complete sensor system including optical design, fixation, calibration, and processing and is demonstrated through comparison with an appropriate reference. For DormoVision X™ Home PSG and In-Lab PSG, that evidence includes testing the sensor in its intended forehead location against arterial blood measurements [2].

Clinical research identifies several reasons why forehead measurement can be useful:

  • Performance during reduced peripheral perfusion. Under vasoconstrictive conditions associated with severe shock and high-dose vasopressor treatment, forehead oximetry produced fewer errors than finger oximetry: 15% versus 32% of measurements differed from arterial blood saturation by more than three percentage points, with the finger sensor failing to provide readings in four patients [7].
  • Higher temporal precision in detecting oxygenation changes. During induced oxygenation changes in anesthetized patients, forehead reflectance oximetry detected desaturation and resaturation earlier than finger transmission oximetry, supporting higher temporal precision in tracking these changes. The forehead sensor detected the decline to 95% SpO₂ 12 seconds earlier, based on the difference in median response times [8].
  • Reduced artifacts during overnight monitoring. In simultaneous recordings from 41 patients undergoing polysomnography, forehead oximetry had the fewest artifact occurrences, while finger oximetry had the most signal dropouts [9].
02
Validation area Skin pigmentation
SpO₂ Accuracy Across Skin Tones

The PPG of DormoVision X™ Home PSG and In-Lab PSG underwent dedicated clinical validation for the assessment of SpO₂ accuracy across all skin tones range. The study compared sensor measurements directly with arterial blood oxygen saturation, providing device-specific evidence of performance across the pigmentation range evaluated [1, 2].

Skin pigmentation was explicitly addressed in the study design through:

  • Broad representation of skin tones. Participants represented Fitzpatrick skin types I–VI, ranging from very fair to deeply pigmented skin. Skin characteristics were additionally documented using the Monk Skin Tone Scale and Individual Typology Angle, supporting assessment of pigmentation beyond ethnicity alone.
  • Assessment across normal and reduced oxygen levels. Sensor readings were compared with arterial measurements across 70-100% oxygen saturation, extending the evaluation beyond normal resting oxygen levels [2].
The study reported no systematic pigmentation related performance differences. Darker pigmentation was not associated with higher aggregate measurement error, with the dark pigmentation subgroup showing the lowest reported RMSE. Full subgroup results are presented in Table 1 [1].
Table 1. SpO2 accuracy by skin-pigmentation group
Skin-pigmentation group Reported SpO2 RMSE
Light 3.18 percentage points
Medium 2.53 percentage points
Dark 1.57 percentage points
RMSE, root-mean-square error. Source: [1].
03
Validation area Body position
SpO₂ Performance Across Body Positions

The PPG of DormoVision X™ Home PSG and In-Lab PSG underwent dedicated clinical testing to evaluate SpO₂ performance across different sleeping positions. A prospective study compared DormoVision X™ Home PSG and In-Lab PSG readings with a Nonin 7500 finger pulse oximeter, providing device specific evidence of measurement agreement across the positions evaluated [3].

The study addressed positional performance through:

  • Assessment across common sleeping positions. Ten healthy volunteers were tested while lying prone, on their side, and supine, representing three common sleeping positions.
  • Testing across normal and reduced oxygen levels. Measurements were collected during controlled, stable oxygen-saturation plateaus spanning 70–100%, extending the assessment beyond normal resting oxygen levels.
  • Additional assessment after positional changes. Eight participants also provided measurements after moving to seated and standing positions, at oxygen-saturation levels within the 90–100% range.

Across 374 paired measurements, the overall difference between the reference oximeter and DormoVision X™ Home PSG and In-Lab PSG corresponded to an RMSE of 2.96 percentage points. Among sleeping positions, the lowest RMSE was 2.23 percentage points in the prone position. Position-specific results are presented in Table 2 [3].

Table 2. SpO2 agreement with the reference oximeter by body position
Position Paired measurements Evaluated saturation range Reported RMSE
Prone 127 70–100% 2.23 percentage points
Side 122 70–100% 3.73 percentage points
Supine 109 70–100% 3.02 percentage points
Seated 8 90–100% 1.73 percentage points
Standing 8 90–100% 1.17 percentage points
Overall 374 70–100% 2.96 percentage points
RMSE, root-mean-square error. Source: [3].
* The DormoVision X™ Platform is the commercial platform utilizing the FDA-cleared Dormotech NLab™ and Vlab™ physiological data recording systems (510(k) K242290 [1] and 510(k) K230148 [10]). The platform is indicated for prescription use by or on the order of a licensed physician for the acquisition and display of comprehensive physiological sleep parameters in both supervised (clinical/laboratory) and unsupervised (home) environments for patients greater than 6 years of age. Automated scoring and analytical features function strictly as data-visualization aids and do not supersede manual review or clinical interpretation by a qualified sleep technologist or physician.
References
1. Dormotech Medical Ltd. 510(k) summary: K242290. 2025 Jan 8. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242290.pdf
2. Vital Signs Research Group. The accuracy of the Dormotech DormoVision X PPG Sensor during stable hypoxia plateaus. Unpublished study report. Principal investigator: G. Stratmann. San Francisco (CA); 2024 May 28.
3. Vital Signs Research Group. The accuracy of Dormotech DormoVision X PPG Sensor during stable hypoxia plateaus in different sleeping positions. Unpublished study report. Principal investigator: G. Stratmann. San Francisco (CA); 2024 Nov 1.
4. Fox BD, Shihab M, Nassir A, Kushinsky D, Barnea O, Tal A. Validation of a novel mask-based device for monitoring of comprehensive sleep parameters and sleep disordered breathing. Sleep Breath. 2025;29:83. doi: 10.1007/s11325-025-03250-1
5. Fox BD, Shihab M, Kushinsky D, Lanir-Azaria S, Nassir A, Barnea O, et al. Advancing sleep testing for children: in-laboratory validation of a Type 2 sleep-monitoring system designed for home-based pediatric assessment. Unpublished manuscript; 2026.
6. Nitzan M, Romem A, Koppel R. Pulse oximetry: fundamentals and technology update. Med Devices (Auckl). 2014;7:231–9. doi: 10.2147/MDER.S47319
7. Nesseler N, Frénel JV, Launey Y, Morcet J, Mallédant Y, Seguin P. Pulse oximetry and high-dose vasopressors: a comparison between forehead reflectance and finger transmission sensors. Intensive Care Med. 2012;38:1718–22. doi: 10.1007/s00134-012-2659-0
8. Choi SJ, Ahn HJ, Yang MK, Kim CS, Sim WS, Kim JA, et al. Comparison of desaturation and resaturation response times between transmission and reflectance pulse oximeters. Acta Anaesthesiol Scand. 2010;54(2):212–7. doi: 10.1111/j.1399-6576.2009.02101.x
9. Strickland KR, Brown CJ, Wilks L, Dunn PK, Holmes MA. Does measurement site matter? A comparison between finger, forehead, and toe pulse oximetry measurements in polysomnography. J Sleep Res. 2026:e70400. doi: 10.1111/jsr.70400
10. Dormotech Medical Ltd. 510(k) summary: K230148. 2023 Sep 11. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf23/K230148.pdf